Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Dr Lihua Zheng China

AnHeart Therapeutics is an oncology-focused clinical stage biopharmaceutical company headquartered in Hangzhou, China with offices in Beijing, Shanghai and New York. The company’s pipeline consists of three clinical stage assets: Taletrectinib, a next-gen ROS1 and NTRK inhibitor currently in Phase 2; an mIDH1 inhibitor ready for Phase 2 for low grade glioma, cholangiocarcinoma, AML and other tumors; and an AXL inhibitor in Phase 1 for overcoming resistance in various tumors.
Website:
http://anhearttherapeutics.com/en/home/
Company Size (Fulltime employees)
11-50
Year of foundation
2018
Partnering Objectives
Please specify your partnering goal
1/Funding Raising for Series B; 2/Pipeline Asset EU and Korea out licensing; 3/In licensing new clinical PoC oncology assets
Headquartner in China
Yes
Biotech/Pharma Category
Assets Information 1
Taletrectinib|next-gen ROS1/NTRK inhibitor, the leading program, currently in a Phase 2 trial in China and ex-China global trials to start in early 2021|ROS1+ NSCLC|Global
Assets Information 2
AB-218/DS-1001|a potentially best-in-class mIDH-1 inhibitor in co-development with Daiichi Sankyo (Japan rights), to start with ex-Japan global Phase 2 trials in glioma and conduct preclinical and clinical POC studies in other indications|IDH1+ Lower Grade Glioma|ex-Japan
Assets Information 3
AB-329/DS-1205|a potentially best-in-class AXL inhibitor, to start with preclinical and clinical POC studies in multiple indications|combo with PD-1 ab for NSCLC|Global
Biotech/Pharma Asset Stage
Dr Lihua Zheng
AnHeart Therapeutics
LinkedIn logo CBO & co-Founder 
Functionality
Management

Linda Zheng China

A French PHARMA & cosmetics company
Website:
www.Pierre-Fabre.com
Partnering Objectives
Headquartner in China
No
Biotech/Pharma Category
Pierre Fabre Medicament China
Senior Market Access & Health Economics Director 

Jia Zhilong China

a large hospital
Website:
www.301hospital.com.cn
Partnering Objectives
Headquartner in China
Yes
Chinese PLA general hospital
assistant professor 

Sandra Zhong China

Partnering Objectives
Suzhou Kintor Pharmaceuticals, Inc.
BD Director 

yanfei zhou China

ZhongXi Capital focus on biomedical investment，fiancing，consulting and other capital market business.
Website:
无
Partnering Objectives
Headquartner in China
Yes
ZhongXi Capital
高级投资经理 

Min Zhou China

Hainan Haiyao, a Chinese public company with stock code of 000566, is established in 1965, mainly focused on some severe diseases such as infection, tumor, digestion system etc.
Website:
www.haiyao.com.cn
Partnering Objectives
Headquartner in China
Yes
Hainan Haiyao Co. , Ltd
BD Director 

ping zhou China

略
Website:
www.jitri.org
Partnering Objectives
Headquartner in China
Yes
江苏省产业技术研究院
senior business manager 

Kaiqi Zhou China

Top medical device company in China focused on cardiovascular, surgical robotics and ten more fields.
Website:
www.microport.com
Partnering Objectives
Headquartner in China
Yes
Shanghai MicroPort Medical
BD Associate 

James Zhou China

A biotech company headquartered in China with clinically validated integrated platform for drug discovery and development.  We focus on oncology and inflammatory disease. There are four projects on Phase I clinical stage.

Website:
http://www.transtherabio.com/
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
Nanjing TransTherabio
Director 

HAN ZHOU China

Big pharm in China
Website:
www.cppharm.com
Partnering Objectives
Headquartner in China
Yes
CP pharm
投资经理